Back to search

Niu-Chang-Chih · 2014 · Randomized Controlled Trial

Medium relevance

Effectiveness of a novel herbal agent MB-6 as a potential adjunct to 5-fluoracil-based chemotherapy in colorectal cancer.

Antrodia camphorata

OncologyCognition & nervesLiver support
SpeciesNiu-Chang-Chih
JournalNutrition research (New York, N.Y.)
Year2014

Key points

  • Based on this, we hypothesized that MB-6 would increase the effectiveness of chemotherapy in patients with colon cancer
  • In a rodent study, MB-6, in combination with leucovorin/5-fluorouracil chemotherapy, increased the survival rate and life span of colon cancer tumor-bearing BALB/c mice as compared with treatment with chemotherapy alone
  • In a proof-of-concept clinical study, 72 patients with metastatic colorectal cancer were randomized to receive leucovorin, 5-fluorouracil, and oxaliplatin in combination with either MB-6 or placebo for 16 weeks
  • Up to 77 weeks after treatment, there was follow-up with the patients
  • No significant difference in the best overall response rate and overall survival was observed between the 2 groups
  • Patients in the MB-6 group had a significantly lower disease progression rate than patients in the placebo group, during the study period (0.0% vs 15.8%, P =.026)

Metadata-grounded summary

Citation abstract

Natural products, such as fermented soybeans, have been used to treat various physical conditions, including cancer. MB-6 is a botanical preparation composed of fermented soybean extract, green tea extract, Antrodia camphorata mycelia, spirulina, grape seed extract, and curcumin extract. Based on this, we hypothesized that MB-6 would increase the effectiveness of chemotherapy in patients with colon cancer. In a rodent study, MB-6, in combination with leucovorin/5-fluorouracil chemotherapy, increased the survival rate and life span of colon cancer tumor-bearing BALB/c mice as compared with treatment with chemotherapy alone. In a proof-of-concept clinical study, 72 patients with metastatic colorectal cancer were randomized to receive leucovorin, 5-fluorouracil, and oxaliplatin in combination with either MB-6 or placebo for 16 weeks. The primary outcome was the best overall response, and secondary outcomes included progression-free survival, overall survival, and adverse effects. Up to 77 weeks after treatment, there was follow-up with the patients. No significant difference in the best overall response rate and overall survival was observed between the 2 groups. Patients in the MB-6 group had a significantly lower disease progression rate than patients in the placebo group, during the study period (0.0% vs 15.8%, P =.026). The placebo group had a significantly higher incidence of adverse events at least grade 4 compared with the MB-6 group (28.9% vs 2.9%, respectively, P =.004) and a significantly higher occurrence of increased serum creatinine compared with the MB-6 group (29% vs 5.9%, P =.014). MB-6 is a promising botanical supplement that may increase the effectiveness of chemotherapy in patients with metastatic colorectal cancer.

Citation

Chen WT, Yang TS, Chen HC, Chen HH, Chiang HC, Lin TC, et al. (2014). Effectiveness of a novel herbal agent MB-6 as a potential adjunct to 5-fluoracil-based chemotherapy in colorectal cancer. Nutrition research (New York, N.Y.) https://doi.org/10.1016/j.nutres.2014.06.010 PMID: 25150117

Open citation